This article is more than 5 years old. Information may no longer be current.

CoAlign receives clearance for expandable interbody fusion device

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CoAlign Innovations Inc. announced that its AccuLIF XL lateral expandable interbody fusion devices have received marketing clearance from the FDA.

Employing the lateral approach to address fusion procedures, the system uses low-profile delivery and placement with controlled expansion to provide precise anatomical reconstruction of the spine during fusion surgery. According to a company press release, as expansion occurs, a proprietary system of small titanium steps within the implant deploys to create a rigid, monolithic structure. The AccuLIF system is designed to minimize risk to nerve roots and damage to vertebral body endplates during placement.

“Because the lateral approach represents such a large and growing portion of the spine market, we are excited to add the XL device to the AccuLIF family,” Paul Goeld, executive chairman of CoAlign, stated.